Compare Citius Pharmaceuticals Inc (CTXR) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs IONQ Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while IONQ Inc trades at $39.89 (market cap $15.98B). The key difference: IONQ Inc is far larger — about 1173.3× Citius Pharmaceuticals Inc's market cap, and IONQ Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and IONQ Inc for 33 Days on average.
| CTXR | IONQ | |
|---|---|---|
Market Cap | $13.62M | $15.98B |
Volume | 132,438 | 22,848,240 |
Sector | Health | Technology |
52-Week High | $1.82 | $82.09 |
52-Week Low | $0.48 | $26.59 |
Typical Hold Time | 17 Days | 33 Days |
Enterprise Value | $3.79M | $13.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% in the last session, with a bearish technical signal from moving averages but bullish oscillators. The company reported $7.1M revenue for the first nine months of fiscal 2026 from LYMPHIR sales, yet net losses persist, with a net income margin of -651.27%. Cash flow remains positive due to financing activities, and analyst consensus is strongly bullish with five buy ratings.
The outlook hinges on commercial execution of LYMPHIR, offering growth potential amid high losses. Key risks include sustained negative profitability, cash burn, and competitive pressures. Investors should weigh the speculative growth narrative against fundamental weaknesses.
IONQ trades at $39.45, down 4.57% today, with bearish technical signals from moving averages but bullish oscillators. The company shows strong revenue growth ($130M in 2025 to $246M projected for 2026) but significant losses (-$510M net income in 2025). Recent Q2 2026 earnings missed expectations, while Q1 and Q4 2025 beat. Analyst consensus is split 50/50 buy/hold with a $62.75 price target, suggesting 59% upside potential from current levels.
IONQ presents high-risk, high-reward potential with substantial revenue growth offset by deep losses and negative margins. The quantum computing sector offers long-term upside if commercialization succeeds, but investors face dilution risk from continued cash burn and execution challenges in scaling technology. Current valuation multiples (P/S 54.74) appear stretched relative to profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
